Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2009-03-17 14:11:07 UTC |
---|
Update Date | 2021-09-14 15:20:32 UTC |
---|
HMDB ID | HMDB0011754 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Methyldopa |
---|
Description | Methyldopa or alpha-methyldopa (brand names Aldomet, Apo-Methyldopa, Dopamet, Novomedopa) is a centrally-acting adrenergic antihypertensive medication. Its use is now deprecated following introduction of alternative safer classes of agents. However it continues to have a role in otherwise difficult to treat hypertension and gestational hypertension (formerly known as pregnancy-induced hypertension). Methyldopa is an aromatic-amino-acid decarboxylase inhibitor in animals and in man. Only methyldopa, the L-isomer of alpha-methyldopa, has the ability to inhibit dopa decarboxylase and to deplete animal tissues of norepinephrine. In man the antihypertensive activity appears to be due solely to the L-isomer. About twice the dose of the racemate (DL-alpha-methyldopa) is required for equal antihypertensive effect. Methyldopa has no direct effect on cardiac function and usually does not reduce glomerular filtration rate, renal blood flow, or filtration fraction. Cardiac output usually is maintained without cardiac acceleration. In some patients the heart rate is slowed. Normal or elevated plasma renin activity may decrease in the course of methyldopa therapy. Methyldopa reduces both supine and standing blood pressure. Methyldopa usually produces highly effective lowering of the supine pressure with infrequent symptomatic postural hypotension. Exercise hypotension and diurnal blood pressure variations rarely occur. Methyldopa, in its active metabolite form, is a central alpha-2 receptor agonist. Using methyldopa leads to alpha-2 receptor-negative feedback to sympathetic nervous system (SNS) (centrally and peripherally), allowing peripheral sympathetic nervous system tone to decrease. Such activity leads to a decrease in total peripheral resistance (TPR) and cardiac output. When introduced it was a mainstay of antihypertensive therapy, but its use has declined, with increased use of other safer classes of agents. One of its important present-day uses is in the management of pregnancy-induced hypertension, as it is relatively safe in pregnancy compared to other antihypertensive drugs (Wikipedia ). |
---|
Structure | C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O InChI=1S/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/m0/s1 |
---|
Synonyms | Value | Source |
---|
(2S)-2-Amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid | ChEBI | (S)-(-)-alpha-Methyldopa | ChEBI | 3-Hydroxy-alpha-methyl-L-tyrosine | ChEBI | Alpha Medopa | ChEBI | alpha-Methyl dopa | ChEBI | alpha-Methyl-beta-(3,4-dihydroxyphenyl)-L-alanine | ChEBI | alpha-Methyl-L-3,4-dihydroxyphenylalanine | ChEBI | alpha-Methyldihydroxyphenylalanine | ChEBI | alpha-Methyldopa | ChEBI | Alphamethyldopa | ChEBI | AMD | ChEBI | L(-)-beta-(3,4-Dihydroxyphenyl)-alpha-methylalanine | ChEBI | L-(-)-3-(3,4-Dihydroxyphenyl)-2-methylalanine | ChEBI | L-(-)-alpha-Methyl-beta-(3,4-dihydroxyphenyl)alanine | ChEBI | L-(alpha-MD) | ChEBI | L-2-Amino-2-methyl-3-(3,4-dihydroxyphenyl)propionic acid | ChEBI | L-3-(3,4-Dihydroxyphenyl)-2-methylalanine | ChEBI | L-alpha-Methyl-3,4-dihydroxyphenylalanine | ChEBI | L-alpha-Methyldopa | ChEBI | L-Methyl dopa | ChEBI | Levo-3-(3,4-dihydroxyphenyl)-2-methylalanine | ChEBI | Methyl-L-dopa | ChEBI | Methyldopa anhydrous | ChEBI | Methyldopum | ChEBI | Metildopa | ChEBI | Aldomet | Kegg | (2S)-2-Amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoate | Generator | (S)-(-)-a-Methyldopa | Generator | (S)-(-)-Α-methyldopa | Generator | 3-Hydroxy-a-methyl-L-tyrosine | Generator | 3-Hydroxy-α-methyl-L-tyrosine | Generator | a Medopa | Generator | Α medopa | Generator | a-Methyl dopa | Generator | Α-methyl dopa | Generator | a-Methyl-b-(3,4-dihydroxyphenyl)-L-alanine | Generator | Α-methyl-β-(3,4-dihydroxyphenyl)-L-alanine | Generator | a-Methyl-L-3,4-dihydroxyphenylalanine | Generator | Α-methyl-L-3,4-dihydroxyphenylalanine | Generator | a-Methyldihydroxyphenylalanine | Generator | Α-methyldihydroxyphenylalanine | Generator | a-Methyldopa | Generator | Α-methyldopa | Generator | L(-)-b-(3,4-Dihydroxyphenyl)-a-methylalanine | Generator | L(-)-Β-(3,4-dihydroxyphenyl)-α-methylalanine | Generator | L-(-)-a-Methyl-b-(3,4-dihydroxyphenyl)alanine | Generator | L-(-)-Α-methyl-β-(3,4-dihydroxyphenyl)alanine | Generator | L-(a-MD) | Generator | L-(Α-MD) | Generator | L-2-Amino-2-methyl-3-(3,4-dihydroxyphenyl)propionate | Generator | L-a-Methyl-3,4-dihydroxyphenylalanine | Generator | L-Α-methyl-3,4-dihydroxyphenylalanine | Generator | L-a-Methyldopa | Generator | L-Α-methyldopa | Generator | (-)-a-Methyldopa | HMDB | (-)-alpha-Methyldopa | HMDB | (-)-Methyldopa | HMDB | 2-Methyl-3-(3,4-dihydroxyphenyl)alanine | HMDB | 3,4-Dihydroxy-2-methylphenylalanine (acd/name 4.0) | HMDB | a-Methyl-L-dopa | HMDB, Generator | Aldoclor-150 | HMDB | Aldoclor-250 | HMDB | Aldometil | HMDB | Aldoril 15 | HMDB | Aldoril 25 | HMDB | Aldoril D30 | HMDB | Aldoril D50 | HMDB | alpha-Methyl-L-dopa | HMDB, MeSH | apo Methyldopa tab 125MG | HMDB | apo Methyldopa tab 250MG | HMDB | apo Methyldopa tab 500MG | HMDB | apo-Methyldopa | HMDB, MeSH | Bayer 1440 L | HMDB | Baypresol | HMDB | Becanta | HMDB | Dopamet | HMDB, MeSH | Dopamethyperpax | HMDB | Dopatec | HMDB | Dopegyt | HMDB, MeSH | Grospisk | HMDB | Hyperpax | HMDB | Hypolag | HMDB | L(-)-a-Methylalanine | HMDB | L(-)-alpha-Methylalanine | HMDB | L-(-)-3-(3,4-Dihydroxyphenyl)-2-methyl-alanine | HMDB | L-(-)-a-Methyl-a-methyl-aldomin | HMDB | L-(-)-alpha-Methyl-alpha-methyl-aldomin | HMDB | L-a-Methyl-(3, 4-dihydroxyphenyl)alanine | HMDB | L-alpha-Methyl-(3, 4-dihydroxyphenyl)alanine | HMDB | Medomet | HMDB | Medopa | HMDB | Medopal | HMDB | Medopren | HMDB | Methoplain | HMDB | Methyldopa 125 tab 125MG | HMDB | Methyldopa 250 tab | HMDB | Methyldopa 500 tab 500MG | HMDB | Methyldopate | HMDB, MeSH | Methyldopate HCL | HMDB | novo-Medopa tab 125MG | HMDB | novo-Medopa tab 250MG | HMDB | novo-Medopa tab 500MG | HMDB | Novomedopa | HMDB | Nu-medopa | HMDB, MeSH | Nu-medopa tab 125MG | HMDB | Nu-medopa tab 250MG | HMDB | Nu-medopa tab 500MG | HMDB | Presinol | HMDB | Presolisin | HMDB | Sedometil | HMDB | Sembrina | HMDB, MeSH | Alphapharm brand OF methyldopa | MeSH, HMDB | Apotex brand OF methyldopa | MeSH, HMDB | Merck brand OF methyldopa | MeSH, HMDB | Nu pharm brand OF methyldopa | MeSH, HMDB | Dopergit | MeSH, HMDB | Hydopa | MeSH, HMDB | Merck sharp and dohme brand OF methyldopa | MeSH, HMDB | Methyldopa orion brand | MeSH, HMDB | Nu-pharm brand OF methyldopa | MeSH, HMDB | Orion brand OF methyldopa | MeSH, HMDB | Rhône poulenc rorer brand OF methyldopa | MeSH, HMDB | Rhône-poulenc rorer brand OF methyldopa | MeSH, HMDB | Dopegit | MeSH, HMDB | Methyldopa apotex brand | MeSH, HMDB | Methyldopa biopat brand | MeSH, HMDB | Methyldopa clonmel brand | MeSH, HMDB | Methyldopa merck brand | MeSH, HMDB | Nu medopa | MeSH, HMDB | alpha Methyl L dopa | MeSH, HMDB | alpha Methyldopa | MeSH, HMDB | apo Methyldopa | MeSH, HMDB | Biopat brand OF methyldopa | MeSH, HMDB | Cahill may roberts brand OF methyldopa | MeSH, HMDB | Clonmel brand OF methyldopa | MeSH, HMDB | Meldopa | MeSH, HMDB | Methyldopa alphapharm brand | MeSH, HMDB | Methyldopa nu-pharm brand | MeSH, HMDB | Methyldopa | ChEBI | Α-methyl-L-dopa | Generator, HMDB |
|
---|
Chemical Formula | C10H13NO4 |
---|
Average Molecular Weight | 211.2145 |
---|
Monoisotopic Molecular Weight | 211.084457909 |
---|
IUPAC Name | (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid |
---|
Traditional Name | methyldopa |
---|
CAS Registry Number | 555-30-6 |
---|
SMILES | C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O |
---|
InChI Identifier | InChI=1S/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/m0/s1 |
---|
InChI Key | CJCSPKMFHVPWAR-JTQLQIEISA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as phenylpropanoic acids. Phenylpropanoic acids are compounds with a structure containing a benzene ring conjugated to a propanoic acid. |
---|
Kingdom | Organic compounds |
---|
Super Class | Phenylpropanoids and polyketides |
---|
Class | Phenylpropanoic acids |
---|
Sub Class | Not Available |
---|
Direct Parent | Phenylpropanoic acids |
---|
Alternative Parents | |
---|
Substituents | - 3-phenylpropanoic-acid
- Alpha-amino acid
- D-alpha-amino acid
- Alpha-amino acid or derivatives
- Amphetamine or derivatives
- Phenylpropane
- Catechol
- 1-hydroxy-2-unsubstituted benzenoid
- Aralkylamine
- 1-hydroxy-4-unsubstituted benzenoid
- Phenol
- Monocyclic benzene moiety
- Benzenoid
- Amino acid
- Amino acid or derivatives
- Carboxylic acid derivative
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Organic nitrogen compound
- Primary aliphatic amine
- Organonitrogen compound
- Organooxygen compound
- Primary amine
- Carbonyl group
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Amine
- Organic oxygen compound
- Aromatic homomonocyclic compound
|
---|
Molecular Framework | Aromatic homomonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 300 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 10 at 25 °C | Not Available | LogP | -1.79 | MEYLAN,WM & HOWARD,PH (1995) |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Methyldopa,1TMS,isomer #1 | C[C@](N)(CC1=CC=C(O[Si](C)(C)C)C(O)=C1)C(=O)O | 2081.1 | Semi standard non polar | 33892256 | Methyldopa,1TMS,isomer #2 | C[C@](N)(CC1=CC=C(O)C(O[Si](C)(C)C)=C1)C(=O)O | 2058.6 | Semi standard non polar | 33892256 | Methyldopa,1TMS,isomer #3 | C[C@](N)(CC1=CC=C(O)C(O)=C1)C(=O)O[Si](C)(C)C | 2109.0 | Semi standard non polar | 33892256 | Methyldopa,1TMS,isomer #4 | C[C@@](CC1=CC=C(O)C(O)=C1)(N[Si](C)(C)C)C(=O)O | 2201.4 | Semi standard non polar | 33892256 | Methyldopa,2TMS,isomer #1 | C[C@](N)(CC1=CC=C(O[Si](C)(C)C)C(O[Si](C)(C)C)=C1)C(=O)O | 2042.6 | Semi standard non polar | 33892256 | Methyldopa,2TMS,isomer #2 | C[C@](N)(CC1=CC=C(O[Si](C)(C)C)C(O)=C1)C(=O)O[Si](C)(C)C | 2033.3 | Semi standard non polar | 33892256 | Methyldopa,2TMS,isomer #3 | C[C@@](CC1=CC=C(O[Si](C)(C)C)C(O)=C1)(N[Si](C)(C)C)C(=O)O | 2120.8 | Semi standard non polar | 33892256 | Methyldopa,2TMS,isomer #4 | C[C@](N)(CC1=CC=C(O)C(O[Si](C)(C)C)=C1)C(=O)O[Si](C)(C)C | 2016.4 | Semi standard non polar | 33892256 | Methyldopa,2TMS,isomer #5 | C[C@@](CC1=CC=C(O)C(O[Si](C)(C)C)=C1)(N[Si](C)(C)C)C(=O)O | 2084.6 | Semi standard non polar | 33892256 | Methyldopa,2TMS,isomer #6 | C[C@@](CC1=CC=C(O)C(O)=C1)(N[Si](C)(C)C)C(=O)O[Si](C)(C)C | 2131.5 | Semi standard non polar | 33892256 | Methyldopa,2TMS,isomer #7 | C[C@](CC1=CC=C(O)C(O)=C1)(C(=O)O)N([Si](C)(C)C)[Si](C)(C)C | 2333.0 | Semi standard non polar | 33892256 | Methyldopa,3TMS,isomer #1 | C[C@](N)(CC1=CC=C(O[Si](C)(C)C)C(O[Si](C)(C)C)=C1)C(=O)O[Si](C)(C)C | 2063.2 | Semi standard non polar | 33892256 | Methyldopa,3TMS,isomer #2 | C[C@@](CC1=CC=C(O[Si](C)(C)C)C(O[Si](C)(C)C)=C1)(N[Si](C)(C)C)C(=O)O | 2111.8 | Semi standard non polar | 33892256 | Methyldopa,3TMS,isomer #3 | C[C@@](CC1=CC=C(O[Si](C)(C)C)C(O)=C1)(N[Si](C)(C)C)C(=O)O[Si](C)(C)C | 2082.0 | Semi standard non polar | 33892256 | Methyldopa,3TMS,isomer #4 | C[C@](CC1=CC=C(O[Si](C)(C)C)C(O)=C1)(C(=O)O)N([Si](C)(C)C)[Si](C)(C)C | 2274.7 | Semi standard non polar | 33892256 | Methyldopa,3TMS,isomer #5 | C[C@@](CC1=CC=C(O)C(O[Si](C)(C)C)=C1)(N[Si](C)(C)C)C(=O)O[Si](C)(C)C | 2056.4 | Semi standard non polar | 33892256 | Methyldopa,3TMS,isomer #6 | C[C@](CC1=CC=C(O)C(O[Si](C)(C)C)=C1)(C(=O)O)N([Si](C)(C)C)[Si](C)(C)C | 2264.2 | Semi standard non polar | 33892256 | Methyldopa,3TMS,isomer #7 | C[C@](CC1=CC=C(O)C(O)=C1)(C(=O)O[Si](C)(C)C)N([Si](C)(C)C)[Si](C)(C)C | 2290.5 | Semi standard non polar | 33892256 | Methyldopa,4TMS,isomer #1 | C[C@@](CC1=CC=C(O[Si](C)(C)C)C(O[Si](C)(C)C)=C1)(N[Si](C)(C)C)C(=O)O[Si](C)(C)C | 2114.7 | Semi standard non polar | 33892256 | Methyldopa,4TMS,isomer #1 | C[C@@](CC1=CC=C(O[Si](C)(C)C)C(O[Si](C)(C)C)=C1)(N[Si](C)(C)C)C(=O)O[Si](C)(C)C | 2115.0 | Standard non polar | 33892256 | Methyldopa,4TMS,isomer #1 | C[C@@](CC1=CC=C(O[Si](C)(C)C)C(O[Si](C)(C)C)=C1)(N[Si](C)(C)C)C(=O)O[Si](C)(C)C | 2150.7 | Standard polar | 33892256 | Methyldopa,4TMS,isomer #2 | C[C@](CC1=CC=C(O[Si](C)(C)C)C(O[Si](C)(C)C)=C1)(C(=O)O)N([Si](C)(C)C)[Si](C)(C)C | 2300.3 | Semi standard non polar | 33892256 | Methyldopa,4TMS,isomer #2 | C[C@](CC1=CC=C(O[Si](C)(C)C)C(O[Si](C)(C)C)=C1)(C(=O)O)N([Si](C)(C)C)[Si](C)(C)C | 2212.3 | Standard non polar | 33892256 | Methyldopa,4TMS,isomer #2 | C[C@](CC1=CC=C(O[Si](C)(C)C)C(O[Si](C)(C)C)=C1)(C(=O)O)N([Si](C)(C)C)[Si](C)(C)C | 2378.5 | Standard polar | 33892256 | Methyldopa,4TMS,isomer #3 | C[C@](CC1=CC=C(O[Si](C)(C)C)C(O)=C1)(C(=O)O[Si](C)(C)C)N([Si](C)(C)C)[Si](C)(C)C | 2285.1 | Semi standard non polar | 33892256 | Methyldopa,4TMS,isomer #3 | C[C@](CC1=CC=C(O[Si](C)(C)C)C(O)=C1)(C(=O)O[Si](C)(C)C)N([Si](C)(C)C)[Si](C)(C)C | 2267.9 | Standard non polar | 33892256 | Methyldopa,4TMS,isomer #3 | C[C@](CC1=CC=C(O[Si](C)(C)C)C(O)=C1)(C(=O)O[Si](C)(C)C)N([Si](C)(C)C)[Si](C)(C)C | 2289.7 | Standard polar | 33892256 | Methyldopa,4TMS,isomer #4 | C[C@](CC1=CC=C(O)C(O[Si](C)(C)C)=C1)(C(=O)O[Si](C)(C)C)N([Si](C)(C)C)[Si](C)(C)C | 2276.8 | Semi standard non polar | 33892256 | Methyldopa,4TMS,isomer #4 | C[C@](CC1=CC=C(O)C(O[Si](C)(C)C)=C1)(C(=O)O[Si](C)(C)C)N([Si](C)(C)C)[Si](C)(C)C | 2288.0 | Standard non polar | 33892256 | Methyldopa,4TMS,isomer #4 | C[C@](CC1=CC=C(O)C(O[Si](C)(C)C)=C1)(C(=O)O[Si](C)(C)C)N([Si](C)(C)C)[Si](C)(C)C | 2328.8 | Standard polar | 33892256 | Methyldopa,5TMS,isomer #1 | C[C@](CC1=CC=C(O[Si](C)(C)C)C(O[Si](C)(C)C)=C1)(C(=O)O[Si](C)(C)C)N([Si](C)(C)C)[Si](C)(C)C | 2373.6 | Semi standard non polar | 33892256 | Methyldopa,5TMS,isomer #1 | C[C@](CC1=CC=C(O[Si](C)(C)C)C(O[Si](C)(C)C)=C1)(C(=O)O[Si](C)(C)C)N([Si](C)(C)C)[Si](C)(C)C | 2246.2 | Standard non polar | 33892256 | Methyldopa,5TMS,isomer #1 | C[C@](CC1=CC=C(O[Si](C)(C)C)C(O[Si](C)(C)C)=C1)(C(=O)O[Si](C)(C)C)N([Si](C)(C)C)[Si](C)(C)C | 2162.3 | Standard polar | 33892256 | Methyldopa,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC=C(C[C@](C)(N)C(=O)O)C=C1O | 2343.4 | Semi standard non polar | 33892256 | Methyldopa,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1=CC(C[C@](C)(N)C(=O)O)=CC=C1O | 2324.1 | Semi standard non polar | 33892256 | Methyldopa,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC(=O)[C@@](C)(N)CC1=CC=C(O)C(O)=C1 | 2368.1 | Semi standard non polar | 33892256 | Methyldopa,1TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)N[C@@](C)(CC1=CC=C(O)C(O)=C1)C(=O)O | 2453.6 | Semi standard non polar | 33892256 | Methyldopa,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@@](C)(N)CC1=CC=C(O[Si](C)(C)C(C)(C)C)C(O)=C1 | 2574.8 | Semi standard non polar | 33892256 | Methyldopa,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1=CC=C(C[C@](C)(N)C(=O)O)C=C1O[Si](C)(C)C(C)(C)C | 2574.7 | Semi standard non polar | 33892256 | Methyldopa,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N[C@@](C)(CC1=CC=C(O[Si](C)(C)C(C)(C)C)C(O)=C1)C(=O)O | 2667.6 | Semi standard non polar | 33892256 | Methyldopa,2TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)OC(=O)[C@@](C)(N)CC1=CC=C(O)C(O[Si](C)(C)C(C)(C)C)=C1 | 2536.3 | Semi standard non polar | 33892256 | Methyldopa,2TBDMS,isomer #5 | CC(C)(C)[Si](C)(C)N[C@@](C)(CC1=CC=C(O)C(O[Si](C)(C)C(C)(C)C)=C1)C(=O)O | 2648.1 | Semi standard non polar | 33892256 | Methyldopa,2TBDMS,isomer #6 | CC(C)(C)[Si](C)(C)N[C@@](C)(CC1=CC=C(O)C(O)=C1)C(=O)O[Si](C)(C)C(C)(C)C | 2676.6 | Semi standard non polar | 33892256 | Methyldopa,2TBDMS,isomer #7 | CC(C)(C)[Si](C)(C)N([C@@](C)(CC1=CC=C(O)C(O)=C1)C(=O)O)[Si](C)(C)C(C)(C)C | 2772.1 | Semi standard non polar | 33892256 | Methyldopa,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@@](C)(N)CC1=CC=C(O[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)=C1 | 2752.7 | Semi standard non polar | 33892256 | Methyldopa,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N[C@@](C)(CC1=CC=C(O[Si](C)(C)C(C)(C)C)C(O)=C1)C(=O)O[Si](C)(C)C(C)(C)C | 2815.0 | Semi standard non polar | 33892256 | Methyldopa,3TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N[C@@](C)(CC1=CC=C(O[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)=C1)C(=O)O | 2847.6 | Semi standard non polar | 33892256 | Methyldopa,3TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)OC1=CC=C(C[C@@](C)(C(=O)O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1O | 3009.4 | Semi standard non polar | 33892256 | Methyldopa,3TBDMS,isomer #5 | CC(C)(C)[Si](C)(C)N[C@@](C)(CC1=CC=C(O)C(O[Si](C)(C)C(C)(C)C)=C1)C(=O)O[Si](C)(C)C(C)(C)C | 2782.0 | Semi standard non polar | 33892256 | Methyldopa,3TBDMS,isomer #6 | CC(C)(C)[Si](C)(C)OC1=CC(C[C@@](C)(C(=O)O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=CC=C1O | 2998.2 | Semi standard non polar | 33892256 | Methyldopa,3TBDMS,isomer #7 | CC(C)(C)[Si](C)(C)OC(=O)[C@](C)(CC1=CC=C(O)C(O)=C1)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2975.4 | Semi standard non polar | 33892256 | Methyldopa,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N[C@@](C)(CC1=CC=C(O[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)=C1)C(=O)O[Si](C)(C)C(C)(C)C | 3012.3 | Semi standard non polar | 33892256 | Methyldopa,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N[C@@](C)(CC1=CC=C(O[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)=C1)C(=O)O[Si](C)(C)C(C)(C)C | 2851.4 | Standard non polar | 33892256 | Methyldopa,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N[C@@](C)(CC1=CC=C(O[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)=C1)C(=O)O[Si](C)(C)C(C)(C)C | 2613.2 | Standard polar | 33892256 | Methyldopa,4TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)[C@](C)(CC1=CC=C(O[Si](C)(C)C(C)(C)C)C(O)=C1)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3181.8 | Semi standard non polar | 33892256 | Methyldopa,4TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)[C@](C)(CC1=CC=C(O[Si](C)(C)C(C)(C)C)C(O)=C1)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3007.3 | Standard non polar | 33892256 | Methyldopa,4TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)[C@](C)(CC1=CC=C(O[Si](C)(C)C(C)(C)C)C(O)=C1)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2655.4 | Standard polar | 33892256 | Methyldopa,4TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC1=CC=C(C[C@@](C)(C(=O)O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1O[Si](C)(C)C(C)(C)C | 3220.9 | Semi standard non polar | 33892256 | Methyldopa,4TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC1=CC=C(C[C@@](C)(C(=O)O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1O[Si](C)(C)C(C)(C)C | 2936.4 | Standard non polar | 33892256 | Methyldopa,4TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC1=CC=C(C[C@@](C)(C(=O)O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1O[Si](C)(C)C(C)(C)C | 2725.7 | Standard polar | 33892256 | Methyldopa,4TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)OC(=O)[C@](C)(CC1=CC=C(O)C(O[Si](C)(C)C(C)(C)C)=C1)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3161.6 | Semi standard non polar | 33892256 | Methyldopa,4TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)OC(=O)[C@](C)(CC1=CC=C(O)C(O[Si](C)(C)C(C)(C)C)=C1)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3025.6 | Standard non polar | 33892256 | Methyldopa,4TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)OC(=O)[C@](C)(CC1=CC=C(O)C(O[Si](C)(C)C(C)(C)C)=C1)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2687.3 | Standard polar | 33892256 | Methyldopa,5TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@](C)(CC1=CC=C(O[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)=C1)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3408.0 | Semi standard non polar | 33892256 | Methyldopa,5TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@](C)(CC1=CC=C(O[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)=C1)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3128.9 | Standard non polar | 33892256 | Methyldopa,5TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@](C)(CC1=CC=C(O[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)=C1)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2667.3 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - Methyldopa GC-EI-TOF (Non-derivatized) | splash10-001i-0690000000-f54d986a8144f4a79b82 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Methyldopa GC-EI-TOF (Non-derivatized) | splash10-001i-0690000000-f54d986a8144f4a79b82 | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Methyldopa GC-MS (Non-derivatized) - 70eV, Positive | splash10-00xu-4900000000-739bef9b92ae61fa3997 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Methyldopa GC-MS (3 TMS) - 70eV, Positive | splash10-03l3-6719300000-8507376d6ae27047f468 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Methyldopa GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Methyldopa LC-ESI-qTof , Positive-QTOF | splash10-0g5i-2900000000-2d1c0ec9ad93e208b620 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methyldopa , positive-QTOF | splash10-0g5i-2900000000-2d1c0ec9ad93e208b620 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methyldopa 15V, Negative-QTOF | splash10-01p2-3940000000-04fec0e15e79c768fdc7 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methyldopa 30V, Negative-QTOF | splash10-0002-2910000000-5ab87bad3301cc12d671 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methyldopa 90V, Positive-QTOF | splash10-0wmi-5900000000-8d84c2b3f8d906813668 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methyldopa 75V, Positive-QTOF | splash10-0ik9-2900000000-f0762b6c346fb34404e5 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methyldopa 15V, Positive-QTOF | splash10-014s-0910000000-ef3d681f544c504b6f07 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methyldopa 30V, Positive-QTOF | splash10-014r-0900000000-a11a3fc0536274091e7c | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methyldopa 60V, Positive-QTOF | splash10-03y0-0900000000-20bad18343ec957bca95 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methyldopa 45V, Positive-QTOF | splash10-014r-0900000000-2a78e6a20d8599caab2b | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methyldopa 15V, Positive-QTOF | splash10-014s-0910000000-db2e7c58eec2a2e9f25e | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methyldopa 60V, Positive-QTOF | splash10-03y0-0900000000-4ee772845ee32a944db1 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methyldopa 60V, Positive-QTOF | splash10-0002-1900000000-3efdf92a8af6e42965e2 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methyldopa 60V, Negative-QTOF | splash10-0002-1900000000-4ba9f4555cda937d3883 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methyldopa 45V, Negative-QTOF | splash10-006t-1900000000-aa6c8ce94351767534b1 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methyldopa 75V, Negative-QTOF | splash10-0002-0900000000-cdcf4d0d2fe21483aac5 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methyldopa 10V, Positive-QTOF | splash10-014i-0910000000-3bfdb36173438fdd8a17 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methyldopa 20V, Positive-QTOF | splash10-014i-0900000000-9b6b615025e3da8f5450 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methyldopa 40V, Positive-QTOF | splash10-0600-4900000000-34dc05f00879ecc053bf | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methyldopa 10V, Positive-QTOF | splash10-014i-0910000000-3bfdb36173438fdd8a17 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methyldopa 20V, Positive-QTOF | splash10-014i-0900000000-9b6b615025e3da8f5450 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methyldopa 40V, Positive-QTOF | splash10-0600-4900000000-34dc05f00879ecc053bf | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methyldopa 10V, Negative-QTOF | splash10-03di-4290000000-cdd2c737cabf0ee44d1f | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methyldopa 20V, Negative-QTOF | splash10-000i-9410000000-d1fa6c265dd8ca539a0e | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methyldopa 40V, Negative-QTOF | splash10-007d-6900000000-56bdd61262b97efe050b | 2016-08-03 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum |
|
---|
Disease References | Prostate cancer |
---|
- Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762. [PubMed:19212411 ]
|
|
---|